Skip to the page

Data / Drug companies / Takeda Ireland Ltd.

Takeda Ireland Ltd.: 13 products in the FDA NDC directory, labeler code 66332

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Takeda Ireland Ltd. (labeler code 66332) lists 13 products in the FDA National Drug Code Directory. By type: 13 drugs for further processing. Its main marketing category is drugs for further processing. The newest product started marketing on January 29, 2018.

The request: Watch Takeda Ireland Ltd. (FDA labeler code 66332): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
66332
Products in commercial distribution
13
Packages
13
Finished drugs by generic name
0
Prescription products
0
Over the counter products
0
Started marketing in the last 12 months
0
Earliest marketing start
July 15, 1999
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Drugs for further processing13100%

Products by type

TypeProductsShare
Drugs for further processing13100%

Dosage forms

Dosage formProductsShare
Tablet753.8%
Tablet, film coated430.8%
Tablet, orally disintegrating, delayed release215.4%

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Azilsartan medoxomil and chlorthalidone66332-6003TabletDrugs for further processingJanuary 29, 2018
Azilsartan medoxomil and chlorthalidone66332-6002TabletDrugs for further processingJanuary 29, 2018
Azilsartan medoxomil66332-2003TabletDrugs for further processingJanuary 29, 2018
Azilsartan medoxomil66332-2002TabletDrugs for further processingJanuary 29, 2018
Alogliptin66332-7003Tablet, film coatedDrugs for further processingJanuary 25, 2013
Alogliptin66332-7002Tablet, film coatedDrugs for further processingJanuary 25, 2013
Alogliptin66332-7001Tablet, film coatedDrugs for further processingJanuary 25, 2013
Ramelteon66332-0014Tablet, film coatedDrugs for further processingJuly 22, 2005
Lansoprazole66332-1443Tablet, orally disintegrating, delayed releaseDrugs for further processingAugust 30, 2002
Lansoprazole66332-1442Tablet, orally disintegrating, delayed releaseDrugs for further processingAugust 30, 2002
Pioglitazone hydrochloride66332-0013TabletDrugs for further processingJuly 15, 1999
Pioglitazone hydrochloride66332-0012TabletDrugs for further processingJuly 15, 1999
Pioglitazone hydrochloride66332-0011TabletDrugs for further processingJuly 15, 1999

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.